Want to see AU:IBX full AI Analyst Report?
Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.01
â–²(20.00% Upside)
Action:Reiterated
Date:06/26/26
The score is driven primarily by weak financial performance (zero revenue in 2025, persistent losses, negative equity, and ongoing cash burn), which outweighs only modestly mixed technical signals. Valuation is also constrained by continued losses (negative P/E) and the absence of dividend support.
Positive Factors
Proprietary MagSense platform
The proprietary MagSense magnetic‑nanoparticle imaging platform represents a durable technological advantage. Owning a differentiated detection modality and related IP can create barriers to entry, enabling future licensing, partnerships and clinical differentiation if validation and regulatory progress continue.
Negative Factors
Zero revenue in 2025
Revenue falling to zero in 2025 shows lack of commercial traction and heightens execution risk. Without product sales the company must rely on external capital to fund trials and commercialization, increasing financing, dilution and project‑timing risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary MagSense platform
The proprietary MagSense magnetic‑nanoparticle imaging platform represents a durable technological advantage. Owning a differentiated detection modality and related IP can create barriers to entry, enabling future licensing, partnerships and clinical differentiation if validation and regulatory progress continue.
Read all positive factors
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.94M
Dividend YieldN/A
Average Volume (3M)16.05M
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth-100.00%
EPS Growth68.62%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.02
Shares Outstanding539,936,300
10 Day Avg. Volume7,347,790
30 Day Avg. Volume16,053,124
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Imagion Biosystems Ltd. Business Overview & Revenue Model
Company Description
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic r...
How the Company Makes Money
null...
Imagion Biosystems Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.67M | 1.08M | 473.43K | 232.87K |
| Gross Profit | -8.81K | 2.26M | -279.83K | -3.14M | -2.47M |
| EBITDA | -3.58M | -700.09K | -10.30M | -11.03M | -5.62M |
| Net Income | -4.31M | -2.07M | -12.47M | -9.81M | -6.02M |
Balance Sheet | |||||
| Total Assets | 2.04M | 2.80M | 4.59M | 9.98M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 1.85M | 2.67M | 227.08K | 4.45M | 13.39M |
| Total Debt | 2.56M | 2.85M | 6.04M | 4.60M | 46.02K |
| Total Liabilities | 4.21M | 5.09M | 8.37M | 5.30M | 809.88K |
| Stockholders Equity | -2.16M | -2.28M | -3.79M | 4.68M | 13.31M |
Cash Flow | |||||
| Free Cash Flow | -4.04M | -1.27M | -8.51M | -9.21M | -5.29M |
| Operating Cash Flow | -4.04M | -1.27M | -8.32M | -8.70M | -5.07M |
| Investing Cash Flow | 0.00 | 83.74K | -190.38K | -468.73K | -310.09K |
| Financing Cash Flow | 3.24M | 3.61M | 4.29M | -962.06K | 5.15M |
Imagion Biosystems Ltd. Technical Analysis
Neutral
0.01
Price Trends
0.01
Negative
0.01
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
31.59
Neutral
-150.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IBX, the sentiment is Neutral. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 31.59 is Neutral, neither overbought nor oversold. The STOCH value of -150.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:IBX.
Imagion Biosystems Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$835.19M | 59.57 | 2.05% | 3.51% | 56.28% | 55.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | AU$5.67M | -0.43 | -184.98% | ― | ― | ― | |
42 Neutral | AU$5.94M | -0.71 | 142.99% | ― | -100.00% | 68.62% | |
42 Neutral | AU$13.40M | -1.19 | -23.93% | ― | 9.69% | 52.31% | |
41 Neutral | AU$29.49M | -3.57 | -476.27% | ― | ― | -142.39% | |
39 Underperform | AU$20.65M | -2.81 | -164.22% | ― | ― | 26.04% |
* Healthcare Sector Average
AU:IBX
Imagion Biosystems Ltd.
0.01
>-0.01
-35.29%
AU:GTG
Genetic Technologies
0.04
0.00
0.00%
AU:BDX
BCAL Diagnostics Limited
0.06
>-0.01
-6.67%
AU:RHY
Rhythm Biosciences Ltd.
0.08
-0.03
-26.36%
AU:GSS
Genetic Signatures Ltd.
0.06
-0.26
-81.56%
AU:IDX
Integral Diagnostics Ltd.
2.24
-0.40
-15.02%
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems Plans ASX Share Placement to Raise Capital
Jul 28, 2026
Imagion Biosystems Ltd. has notified the ASX of a proposed issue of up to 17,875,000 ordinary fully paid shares as part of a placement or similar capital-raising structure. The new securities are expected to be issued on 30 November 2026, with the...
Imagion Biosystems Secures Short-Term Non-Dilutive Loan from Executive Chairman
Jul 28, 2026
Imagion Biosystems has secured a non-dilutive short-term funding facility through an unsecured loan agreement with its executive chairman, Robert Proulx, providing up to US$150,000 in working capital. The loan carries an 8% annual interest rate on...
Imagion Biosystems Moves to Fully Virtual General Meeting and Digital Communications
Jul 7, 2026
Imagion Biosystems Limited has called a virtual General Meeting for shareholders to be held on 10 August 2026 at 10:00am AEST via a webinar conferencing facility, with voting eligibility set for registered shareholders as at 8 August 2026. The com...
Imagion Biosystems Extends Siemens Partnership for Pivotal MagSense Trial
Jul 6, 2026
Imagion Biosystems has renewed and extended its collaboration agreement with Siemens Healthineers to support its recently cleared Phase 1b/2 clinical trial of the MagSense HER2 breast cancer imaging agent. Siemens will provide in-kind MRI expertis...
Imagion Biosystems issues new shares and lodges cleansing notice
Jul 2, 2026
Imagion Biosystems has issued 49,346,051 new fully paid ordinary shares at $0.012 per share as part of Tranche 1 of a previously announced placement, and has lodged a cleansing notice under Section 708A of the Corporations Act. The company confirm...
Imagion Biosystems Seeks ASX Quotation for 49 Million New Shares
Jul 1, 2026
Imagion Biosystems has applied for quotation on the ASX of 49,346,051 new fully paid ordinary shares, with an issue date of 30 June 2026. The additional securities, issued under a previously announced transaction, will expand the company’s q...
Imagion Biosystems boosts director’s performance-based equity exposure
Jul 1, 2026
Imagion Biosystems Limited has updated the market on a change in director Robert Romeo Proulx’s interests, reflecting an expansion in his exposure to equity-based incentives. The update details his existing holdings in ordinary shares, liste...
Imagion Biosystems Issues New Unquoted Performance Rights Under Employee Scheme
Jun 25, 2026
Imagion Biosystems has notified the market of the issue of new unquoted equity securities in the form of performance rights under its employee incentive scheme. The company will grant 2,200,000 Class D performance rights and 4,000,000 Class E perf...
Imagion Biosystems Updates Appendix 3B on Director Securities Issue
Jun 25, 2026
Imagion Biosystems Limited has lodged an updated Appendix 3B with the ASX detailing a proposed issue of securities via a placement or similar structure. The filing confirms that the company is seeking quotation of the new securities on the ASX onc...
Imagion Biosystems Plans New Share and Option Placement on ASX
Jun 24, 2026
Imagion Biosystems Limited has notified the Australian Securities Exchange of a proposed placement involving the issue of up to 6,250,000 ordinary fully paid shares and 3,125,000 options. The options are planned to expire in December 2027, with th...
Imagion Biosystems Plans Major Share and Option Issue to Bolster Capital Base
Jun 24, 2026
Imagion Biosystems has notified the ASX of a proposed capital raising through the issue of up to 263,153,949 fully paid ordinary shares and 156,250,000 options expiring in December 2027, with an expected issue date in August 2026. The placement, c...
Imagion Biosystems plans sizeable share issue to bolster capital base
Jun 24, 2026
Imagion Biosystems has lodged an Appendix 3B with the ASX detailing a proposed placement or other type of securities issue of up to 49,346,051 fully paid ordinary shares. The new shares are expected to be issued on 30 June 2026, expanding the comp...
Imagion Biosystems Raises $3.75m to Launch MagSense HER2 Clinical Trial
Jun 24, 2026
Imagion Biosystems has secured firm commitments for a $3.75 million equity placement to sophisticated investors and family offices, priced at $0.012 per share with free attaching listed options, following U.S. FDA clearance of its Investigational ...
Imagion Biosystems Requests Trading Halt Ahead of Capital Raising
Jun 22, 2026
Imagion Biosystems has requested a trading halt on its securities on the Australian Securities Exchange as it prepares a material announcement related to a capital raising. The halt, granted under ASX Listing Rule 17.1, will remain in place until ...
Imagion Biosystems wins FDA IND clearance for MagSense HER2 breast cancer trial
Jun 1, 2026
Imagion Biosystems has received U.S. FDA clearance of its Investigational New Drug application for the MagSense HER2 Imaging Agent, allowing a Phase 1b/2 clinical trial in HER2-positive breast cancer patients to proceed. The approval confirms that...
Imagion Biosystems Options Lapse, Simplifying Capital Structure
May 28, 2026
Imagion Biosystems has reported the expiry of a series of listed options with the ASX code IBXAAT, which were due to expire on 26 May 2026 with an exercise price of $1.496. A total of 699,897 options lapsed unexercised, resulting in a reduction of...
Imagion Biosystems AGM Backs Board, Incentive Plan and Capital Flexibility
May 26, 2026
Imagion Biosystems reported the results of its annual general meeting held on 26 May 2026, with all resolutions put to shareholders passed by the required majorities. The adoption of the remuneration report and the election of directors, including...
Imagion Biosystems outlines molecular MRI strategy and investor risk caveats
May 26, 2026
Imagion Biosystems has released an investor presentation outlining its focus on molecular MRI as a next generation imaging platform for early cancer detection. The deck is presented as informational only, with extensive legal and risk disclosures ...
Imagion Biosystems advances MagSense cancer imaging with first FDA IND filing
May 26, 2026
Imagion Biosystems used its 2025 Annual General Meeting to underline progress in developing its MagSense molecular imaging platform, which aims to offer safer, more targeted MRI contrast agents than conventional media and a competitive alternative...
Imagion Biosystems director adjusts holding of performance options
May 8, 2026
Imagion Biosystems has reported a change in the equity interests held by director Robert Romeo Proulx, as disclosed in an updated notice to the ASX. The filing details the disposal of 50,000 unlisted performance options at no consideration, adjust...
Imagion Biosystems Options Lapse, Trimming Potential Dilution
May 4, 2026
Imagion Biosystems Limited has reported the cessation of a tranche of listed options on the ASX, identified by the code IBXAAA, which expired unexercised on 1 May 2026. The expiry of 68,750 options with an exercise price of $1.12 slightly reduces ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.